Compared to the general population, a woman with a confirmed BRCA1 or BRCA2 mutation is at greater risk of developing cancer during her lifetime—up to an 85% risk of breast cancer and up to a 40% risk of ovarian cancer. Her children, siblings and parents have a 50% chance of having the same autosomal dominant mutation and facing comparable risks.
WebinarsView All Webinars >
Whitney Dodge, LCGC, Genetic Counselor explains the clinical signs and symptoms of FSHD and discusses the differences between Southern blot and molecular combing testing methodologies.... Read more
Dr. Kapoor discusses sepsis and its impact on healthcare. She provides an overview of procalcitonin testing and its clinical utility in the diagnosis and for... Read more
Attendees learn how Resistance Associated Variants (RAV) affect Hepatitis C Virus treatment, understand what clinical trials tell us about resistance testing, and learn how to... Read more
Expert InsightsView All Expert Insights >
PublicationsView All Publications >
Nassar A, Cohen C, Zhou W, Lynch KA, Barker EA, Vanderbilt BL, Thompson J, Heyman ER, Olson A, Lange H, Siddiqui MT.Bandino JP, Kazlouskaya V, Ergin S, Moles-Proveda P, Cleaver NJ, Kabigting FD, Shackelton JB, Thieu K
J Cutan Pathol 2015
Determination of HIV-1 coreceptor tropism using proviral DNA in women before and after viral suppression.
Nassar A, Cohen C, Zhou W, Lynch KA, Barker EA, Vanderbilt BL, Thompson J, Heyman ER, Olson A, Lange H, Siddiqui MT.Burger H, Weiser B, Gao W, Anastos K, Young M
AIDS Res Ther 2015;12:11
Use of a picosecond pulse duration laser with specialized optic for treatment of facial acne scarring.
Nassar A, Cohen C, Zhou W, Lynch KA, Barker EA, Vanderbilt BL, Thompson J, Heyman ER, Olson A, Lange H, Siddiqui MT.Brauer JA, Kazlouskaya Y, Alabdulrazzaq H, Bae YS, Bernstein LJ, Anolik R, Geronemus RG
JAMA Dermatol 2015;151:278-284